Wedbush Predicts Vor Biopharma’s Q4 Earnings (NASDAQ:VOR)

Vor Biopharma Inc. (NASDAQ:VOR) – Research analysts at Wedbush issued their Q4 2025 EPS estimates for shares of Vor Biopharma in a research note issued to investors on Tuesday, November 25th. Wedbush analyst M. Fan anticipates that the company will earn ($1.11) per share for the quarter. Wedbush has a “Neutral” rating on the stock. Wedbush also issued estimates for Vor Biopharma’s Q1 2026 earnings at ($1.25) EPS, Q2 2026 earnings at ($1.43) EPS, Q3 2026 earnings at ($0.93) EPS, Q4 2026 earnings at ($1.08) EPS, FY2026 earnings at ($4.52) EPS, FY2027 earnings at ($9.16) EPS, FY2028 earnings at ($5.74) EPS and FY2029 earnings at ($4.43) EPS.

A number of other equities research analysts have also commented on VOR. Stifel Nicolaus upgraded Vor Biopharma from a “hold” rating to a “buy” rating and set a $55.00 price target on the stock in a research report on Wednesday, September 24th. Robert W. Baird upgraded Vor Biopharma from a “neutral” rating to an “outperform” rating and upped their target price for the company from $20.00 to $64.00 in a report on Wednesday, October 15th. HC Wainwright decreased their target price on shares of Vor Biopharma from $55.00 to $32.00 and set a “buy” rating for the company in a research report on Friday, November 14th. Baird R W upgraded shares of Vor Biopharma from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, October 15th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vor Biopharma in a research note on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Vor Biopharma has a consensus rating of “Hold” and a consensus target price of $73.17.

Vor Biopharma Stock Performance

Shares of NASDAQ:VOR opened at $7.95 on Thursday. The company has a market cap of $82.76 million, a price-to-earnings ratio of -0.02 and a beta of 2.02. Vor Biopharma has a 12-month low of $2.62 and a 12-month high of $65.80. The stock’s fifty day moving average is $24.64.

Vor Biopharma (NASDAQ:VOR) last issued its quarterly earnings results on Thursday, November 13th. The company reported ($3.33) EPS for the quarter, missing analysts’ consensus estimates of ($3.06) by ($0.27).

Institutional Investors Weigh In On Vor Biopharma

A number of large investors have recently bought and sold shares of the stock. Fcpm Iii Services B.V. bought a new stake in Vor Biopharma in the third quarter valued at $18,496,000. Jane Street Group LLC acquired a new stake in shares of Vor Biopharma in the 1st quarter valued at about $140,000. OMERS ADMINISTRATION Corp bought a new stake in Vor Biopharma in the 1st quarter valued at about $100,000. Millennium Management LLC raised its stake in Vor Biopharma by 122.5% during the 3rd quarter. Millennium Management LLC now owns 24,764 shares of the company’s stock worth $1,207,000 after buying an additional 134,764 shares during the period. Finally, Ariose Capital Management Ltd acquired a new position in Vor Biopharma during the 3rd quarter worth approximately $5,368,000. 97.29% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Vor Biopharma news, major shareholder Reprogrammed Interchange Llc sold 11,616 shares of the stock in a transaction that occurred on Monday, October 20th. The stock was sold at an average price of $30.05, for a total transaction of $349,060.80. Following the transaction, the insider directly owned 1,167,109 shares in the company, valued at approximately $35,071,625.45. This represents a 0.99% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Ra Capital Management, L.P. sold 24,579 shares of the firm’s stock in a transaction that occurred on Thursday, October 30th. The stock was sold at an average price of $25.12, for a total transaction of $617,424.48. Following the sale, the director directly owned 779,652 shares of the company’s stock, valued at approximately $19,584,858.24. This trade represents a 3.06% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 2,327,243 shares of company stock valued at $57,827,859. 0.45% of the stock is currently owned by corporate insiders.

About Vor Biopharma

Vor Biopharma, Inc, a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company’s VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.